IO Biotech, Inc. engages in the development of immune modulating cancer therapies based on its T-win technology platform. The Company’s product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotech’s lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The firm develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME. The firm is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark.
Follow-Up Questions
IO Biotech Inc のCEOは誰ですか？
Dr. Mai-Britt Zocca は IO Biotech Inc の President で、2015 から在籍しています。
IOBT の株価パフォーマンスは？
IOBT の現在の価格は $1 で、最終取引日から 0.44% increased 変動しました。
IO Biotech Inc の主な事業テーマや業界は？
IO Biotech Inc は Biotechnology 業界、セクターは Health Care に属しています。
